TELA Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
TELA Bio, Inc. - overview
Established
2012
Location
Malvern, PA, US
Primary Industry
Medical Devices & Equipment
About
TELA Bio, Inc. develops innovative surgical reconstruction solutions, primarily focusing on soft tissue repair through its flagship product OviTex®, designed to enhance healing while reducing synthetic material usage. Founded in 2012 and headquartered in Malvern, US, TELA Bio, Inc. specializes in surgical reconstruction solutions.
Founded by Antony Koblish, who serves as the CEO, the company has completed 12 deals. The latest round of funding was a Private Placement which raised USD 32. 00 mn. The total amount raised by the company is USD 32.
00 mn, with the most recent deal date on November 8, 2019. TELA Bio specializes in innovative surgical reconstruction solutions, focusing primarily on the repair of soft tissue through its flagship product, OviTex®, a reinforced tissue matrix. OviTex incorporates layers of ovine rumen interwoven with polymer suture, designed to support the body’s natural healing processes while minimizing the use of synthetic materials. This product is intended for use in hernia and abdominal wall reconstruction, addressing the industry's shift away from traditional synthetic meshes due to concerns over long-term complications.
The company’s product portfolio is tailored to meet the unique needs of patients, offering various resorption, stretch, and shape options within the OviTex PRS portfolio, which is specifically formulated for plastic and reconstructive surgery. TELA Bio targets various healthcare markets, primarily serving surgeons, hospitals, and healthcare institutions in North America and Europe, where there is a growing demand for advanced soft-tissue repair solutions. In the most recent year of 2024, TELA Bio generated revenue of USD 69. 30 mn.
The company reported an EBITDA of USD -33. 10 mn. TELA Bio plans to leverage its recent funding, particularly the USD 32. 00 mn raised in August 2022, to drive its growth initiatives.
The company is working on expanding its product offerings with new designs of OviTex® aimed at enhancing surgical outcomes. Furthermore, TELA Bio seeks to penetrate new geographic markets in Asia and South America by 2025, capitalizing on the increasing demand for innovative surgical solutions.
Current Investors
OrbiMed Advisors, Quaker Partners Management, Signet Healthcare Partners
Primary Industry
Medical Devices & Equipment
Sub Industries
Surgical Devices, Medical Supplies
Website
www.telabio.com
Verticals
HealthTech, Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
TELA Bio, Inc. - timeline of key events
TELA Bio, Inc. - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 4,300,000 | 8,300,000 | 15,446,000 | 18,213,000 | 29,463,000 | 41,418,000 | - | - | - |
| % Revenue Growth (YoY) | - | 93.0% | 86.1% | 17.9% | 61.8% | 40.6% | - | - | - |
| EBITDA (USD) | (16,000,000) | (16,200,000) | (18,580,000) | (24,750,000) | (28,916,000) | (37,820,000) | - | - | - |
| Operating Income (USD) | (16,800,000) | (17,500,000) | (19,162,000) | (25,275,000) | (29,451,000) | (39,007,000) | - | - | - |
| Operating Margin | (390.7%) | (210.8%) | (124.1%) | (138.8%) | (100.0%) | (94.2%) | - | - | - |
| % EBITDA Margin | (372.1%) | (195.2%) | (120.3%) | (135.9%) | (98.1%) | (91.3%) | - | - | - |
| NET Income (USD) | (21,300,000) | (21,100,000) | (22,425,000) | (28,794,000) | (33,276,000) | (44,296,000) | - | - | - |
| % Net Margin | (495.3%) | (254.2%) | (145.2%) | (158.1%) | (112.9%) | (106.9%) | - | - | - |
TELA Bio, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.